Therapeutic effect of isovolemic hemodilution with dextran 60 on the impairment of pancreatic microcirculation in acute biliary pancreatitis.
Dextran of different molecular weight (Dx 40, Dx 60/70) has often been evaluated as adjunct treatment of experimental acute pancreatitis. A beneficial effect has been documented by a decrease in its lethality. However, the mechanism of action is poorly understood. A specific effect on the pancreatic microcirculation generally has not been documented and differentiation from unspecific improvement of pancreatic blood flow due to volume expansion has been difficult. This investigation was designed to quantify the effect of dextran on the impairment of pancreatic microcirculation during acute biliary pancreatitis by means of intravital microscopy. Dextran 60 (Dx 60, molecular weight 60,000) was chosen in light of the increase in vascular permeability in the early stage of pancreatitis as demonstrated previously in the same model. Isovolemic hemodilution, i.e., exchange of whole blood for Dx 60 was used as a mode of administration to achieve instantaneous onset of therapy without changes in intravascular volume. In the control group a progressive reduction of pancreatic capillary perfusion commenced 30 minutes after induction of acute pancreatitis, resulting in cessation of nutritive tissue perfusion after 3 hours. In the animals subjected to hemodilution, stabilization of the pancreatic microcirculation was accomplished throughout the observation period of 6 hours. Because volume-related effects could be excluded by the protocol and by monitoring central venous pressure and hematocrit, a specific effect of hemodilution with DX 60 on the pancreatic microcirculation is indicated by our results.
Klar
E
E
Department of General Surgery, University of Heidelberg, West Germany.
Herfarth
C
C
Messmer
K
K
D000208:Acute Disease; D000818:Animals; D002199:Capillary Permeability / Q000502:physiology; D003911:Dextrans / Q000627:therapeutic use*; D006438:Hemodilution; D008833:Microcirculation / Q000503:physiopathology; D010179:Pancreas / Q000098:blood supply*; D010195:Pancreatitis / Q000139:chemically induced / Q000503:physiopathology / Q000628:therapy*; D011817:Rabbits; D013656:Taurocholic Acid / Q000633:toxicity; D014357:Trypsin / Q000633:toxicity
D003911:Dextrans; D013656:Taurocholic Acid; D014357:Trypsin